-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
October 20, 2022 /eMedClub News/--In recent years, the help of new crown vaccines has made mRNA technology more and more mature, Moderna With BioNTech have intensified the layout
of mRNA cancer vaccines.
According to the "Guardian" reported on the 16th, the founder of the German biotechnology company BioNTech said in an interview with the BBC that the company's cancer vaccine may be in place It will be put into use
by 2030.
Previously, Moderna had just announced a collaboration with Merck to develop a personalized mRNA cancer vaccine mRNA-4157/V940 , the fierce competition of large manufacturers in tumor vaccines has gradually emerged
.
since its inception in 2008.
2020 became a major turning point for BioNTech, which quickly changed its R&D strategy due to the outbreak of the epidemic and quickly made efforts
in the field of new crown vaccine research and development.
Its cooperation with Pfizer in the United States to develop and produce the mRNA new crown vaccine BNT162b2 became the first new crown vaccine to enter clinical trials, and was successfully approved for marketing in the United States on August 23, 2021, so BioNTech was successfully out of the circle
.
In fact, the success of BioNTech's new crown vaccine has led to the development
of its mRNA cancer vaccine.
mRNA technology has remained unknown in the decade since its birth because the mRNA industry in most countries around the world has a weak foundation and has not formed a stable and controllable large-scale production supply chain
.
Now things are different
.
BioNTech founder CEO Uğur Şahin also said that BioNTech learned how to make mRNA vaccines faster during the pandemic and better understood how people's immune systems respond
to mRNA.
The urgent development and rapid rollout of coronavirus vaccines has also made drug regulators more adept
at approving vaccines.
"It will definitely accelerate our cancer vaccine
as well.
"
At present, BioNTech has as many as 14 cancer vaccines for bowel cancer, melanoma, ovarian cancer and other cancer types in clinical trials, of which 4 product candidates have been in phase 2 clinical trials
.
In terms of efficacy, BioNTech's cancer vaccine has begun to show good results
.
As early as July 2020, according to the results of the Phase 1 clinical trial of the mRNA cancer vaccine BNT111 in the treatment of advanced melanoma published by BioNTech in Nature, BNT111 encoded 4 tumor-associated antigens that appeared in more than 90% of melanoma patients, showing good safety and preliminary anti-tumor effects
.
In another BNT211 experiment in the treatment of 14 patients with advanced solid tumors, 6 showed partial remission, 5 patients were stable and the target lesion was reduced
.
In addition to demonstrating the overall targeting efficacy, this data also further verifies the feasibility
of mRNA technology beyond the field of infectious diseases.
Baiji Biotech is recruiting senior scientists, salary negotiable, click to view >>>
Moderna holds hands with Merck
Developing personalized cancer vaccines
Moderna's investigational cancer vaccine, mRNA-4157/V940, is designed to stimulate an immune response by generating a T cell responsebased on the mutant characteristics of a patient's tumor.
According to public sources, the phase 2 clinical trial KEYNOTE-942 of the vaccine in combination with Merck's PD-1 antibody Keytruda is still ongoing for the treatment of high-risk melanoma patients
.
The trial is expected to publish clinical data
in the fourth quarter of this year.
It is not difficult to see that the two sides of this cooperation may complement each other's
advantages.
On the one hand, Moderna has made a splash in the pharmaceutical industry with its mRNA vaccines, leading the development of mRNA vaccines around the world
.
As the epidemic calms down, Moderna needs to find new applications for its mRNA technology, and oncology is the first choice
.
On the other hand, Merck's K drug is the world's best-selling PD-1 monoclonal antibody, but its key patent period will expire in 2028, and the active development of K drug and other oncology drugs in combination therapy broadens the indication of K drug to consolidate the position of K drug, and also finds new marketing points for K drug and extends the life cycle
of K drug.
Obviously, for Moderna, the company is also actively exploring another way
out of mRNA cancer vaccines in the post-pandemic era.
According to its interim data of mRNA-4157 combined with Keytruda released in 2020, its efficacy is also remarkable: in 10 HPV-negative patients with head and neck squamous cell carcinoma, the overall response rate was 50%, and the disease control rate (DCR) reached 90%.
Overall, so far, BioNTech and Moderna, the two mRNA vaccine giants, have only approved new crown mRNA vaccines for marketing
.
In the post-pandemic era, both companies have made the development of mRNA cancer vaccines a top priority for future development, and their efficacy is undoubted
.
So, in the competition between these two biopharmaceutical giants, who will rush the line? We'll see!
Resources:
1.
https://mq.
mbd.
baidu.
com
——List of recent popular events——
